News Daily News Andexanet Alfa, Reversal Agent for Factor Xa Inhibitors, Boosts Hemostasis Todd Neale June 05, 2023
News Conference News EuroPCR 2023 ADALA: Low-Dose Apixaban Tops DAPT After LAA Closure Todd Neale May 18, 2023
News Daily News Slight Risk of Interstitial Lung Disease Seen With Certain DOACs Todd Neale November 23, 2022
News Daily News Apixaban Again Linked to Less Bleeding in AF Patients Michael O'Riordan October 31, 2022
News Daily News Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest Michael O'Riordan October 20, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Daily News Fewer Diabetic Complications Seen When NOACs Given for AF L.A. McKeown February 22, 2022
News Daily News Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study Todd Neale December 27, 2021
News Conference News TCT 2021 PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term Todd Neale November 05, 2021
News Conference News ESC 2021 ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting Todd Neale August 28, 2021
News Daily News ABC-Bleeding Score Stratifies Risk in A-fib Patients on OAC and Aspirin Todd Neale September 21, 2020
News Daily News More Evidence of Lower Fracture Risk With DOACs Versus Warfarin Todd Neale May 19, 2020
News Daily News How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions Michael O'Riordan April 22, 2020
News Conference News ACC 2020 Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS Todd Neale April 03, 2020
News Conference News ACC 2020 Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds Todd Neale March 25, 2020